News
-
-
-
COMMUNIQUÉ DE PRESSE
NANOBIOTIX Announces Presentation of First Data from a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer
NANOBIOTIX announces first data from phase 2 trial on JNJ-1900 for stage 3 lung cancer presented by Johnson & Johnson at European Lung Cancer Conference -
-
-
-
-
-
-